First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: May 14, 2024

Gemini Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gemini Therapeutics Inc
Pre-Tax Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
G
Gemini Therapeutics Inc
NASDAQ:GMTX
Pre-Tax Income
-$46.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$6.3B
CAGR 3-Years
23%
CAGR 5-Years
4%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$1.1B
CAGR 3-Years
-18%
CAGR 5-Years
-33%
CAGR 10-Years
-16%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.3B
CAGR 3-Years
-18%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
12%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$4B
CAGR 3-Years
-3%
CAGR 5-Years
10%
CAGR 10-Years
18%

See Also

What is Gemini Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-46.8m USD

Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Pre-Tax Income amounts to -46.8m USD.

What is Gemini Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 1Y
35%

Over the last year, the Pre-Tax Income growth was 35%.